B of A Securities Maintains Buy Rating for Vertex Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
B of A Securities has maintained its Buy rating for Vertex Pharmaceuticals (NASDAQ:VRTX) and increased its price target from $350.00 to $400.00. Vertex Pharmaceuticals' shares are trading up 0.34% over the last 24 hours, at $363.04 per share. A move to $400.00 would account for a 10.18% increase from the current share price.
July 21, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has maintained its Buy rating for Vertex Pharmaceuticals and raised its price target, potentially leading to a 10.18% increase in the share price.
The maintained Buy rating and increased price target by B of A Securities indicates a positive outlook for Vertex Pharmaceuticals. This could lead to increased investor confidence and a potential rise in the share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100